Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

100.53 -0.58 (-0.57%)
Streaming Delayed Price Updated: 3:18 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis Ag ADR

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
38 39 Next >
Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall?
Crispr is planning to begin a registrational test in the first quarter of 2022. 
Via Investor's Business Daily
Global Rizatriptan Market: How Can a Player Gain a Competitive Edge? Merck, Pfizer, Novartis (Sandoz)
QY Research has used its tons of research and analysis experience and deeper knowledge to comprehensively study the global Rizatriptan market. This report promises sound market understanding for better... 
Via SBWire
Global Biologic Drugs Market: What Is Challenging Market Growth? with Top Companies Like: Johnson & Johnson, Merck & Co., Pfizer
Global Biologic Drugs Market : Buyers of the report have access to crucial findings and important data on the global Biologic Drugs market. Players can simply use the report to gain the upper hand in... 
Via SBWire
Biosimilars Market Worth $44.7 Billion by 2026 - Exclusive Report by MarketsandMarkets™
The global biosimilars market is projected to reach $44.7 billion by 2026. Biosimilars Products Market Report provides crucial industry insights that will help your business grow." /> 
Via SBWire
Topics Intellectual Property
Exposures Intellectual Property
Lung Cancer Market Outlook 2021: Big Things Are Happening : Novartis, Pfizer, Merck
Stay up to date with Lung Cancer Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Kidney Cancer Market May See Big Move : Bristol-Myers Squibb, Pfizer, Roche
Stay up-to-date with Kidney Cancer Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
eFFECTOR Therapeutics Stock Gains On Encouraging Preclinical Zotatifin Data In Breast Cancer
eFFECTOR Therapeutics Inc (NASDAQ: EFTR), in collaboration with Baylor College of Medicine, announced the presentation of new positive data for zotatifin in... 
Via Benzinga
Women's Health Care Market Worth $17.8 Billion – Global Industry Segments and Leading Key Players
The global women’s healthcare market is projected to reach USD 17.8 billion by 2024 from USD 9.6 billion in 2019, at a CAGR of 13.2% during the forecast period 
Via SBWire
Global Measles Market: What Risk Will Market Face in Future? with Top Companies Like: Abbott, Biomedical Diagnostics, Johnson & Johnson Services
The report helps players and investors to stay in a competent position in the global Measles market as they gain insights into the market competition, leading segments, top regions, and other vital... 
Via SBWire
Topics Initial Public Offering
Exposures Securities Market
Cannabis Movers & Shakers: TOCC, 1933 Industries, Iter Investments, Greenlane
Former Tilray Exec Steven Yoo Named Texas Original Compassionate Cultivation's New CFO Texas medical cannabis provider,&n... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Global Antibiotics Drugs Market: Which Application Willgain the Lion'S Share? with Top Companies Like:Johnson & Johnson, Sanofi-Aventis, Enanta Pharmaceuticals
QY Research has used its tons of research and analysis experience and deeper knowledge to comprehensively study the global Antibiotics Drugs market. This report promises sound market understanding for... 
Via SBWire
Global Sex Hormones Market: Which Country Will Create the Highest Demand? with Top Companies Like:Novartis, Merck, Sanofi
This report is a compilation of a number of extensive,authentic research studies on the global Sex Hormones market that help the reader to gain profound knowledge of each and every aspect of the... 
Via SBWire
September Update: The Conservative Pot Stocks Index Continued To Outperform
Reticent about investing in the seed-to-sale sector? Perhaps you should consider investing in more conservative cannabis-related companies, which have lost less YTD. 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
Global Megestrol Industry Analysis and Trends Forecast to 2027:Pfizer, Sandoz, GSK
The global Megestrol market is extensively evaluated by seasoned research analysts to help readers to expand their market knowledge and become aware of future market changes ahead of time. 
Via SBWire
Global Biological Drugs Industry Analysis Report 2021:Bristol-Myers Squibb, Eli Lilly, Takeda
Buyers of the report have access to crucial findings and important data on the global Biological Drugs market. Players can simply use the report to gain the upper hand in the market competition. 
Via SBWire
Global Biosimilars Industry Analysis Report 2021:Pfizer, Novartis, Biocon
The new report on the global Biosimilars market comes out as an extremely useful resource that helpsplayers to gain a competitive edge over their toughest competitors. It can be customized as per... 
Via SBWire
Death Cross Looms Over Novartis Investors
If history is any guide, there may be trouble ahead for shares of Novartis(NYSE:NVS). A so-called "death cross" has formed on its chart and, not surprisingly, this could... 
Via Benzinga
A Bit Of A Recovery
While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week. 
Via Talk Markets
Novartis and Medicines for Malaria Venture Report Positive Results for Phase 2b Study of Novel Ganaplacide/Lumefantrine Combination in Children With Malaria
SOURCE: Novartis 
Via 3BL Media
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Novartis Posts New Data Reinforcing Efficacy, Convenience Of Cosentyx Autoinjector In Psoriasis
Novartis AG (NYSE: NVS) announced data from an international Phase 3b study of Cosentyx (secukinumab) in plaque psoriasis. Data showed that treatment with Cosentyx... 
Via Benzinga
This Potential Indication Could Be a Winner for Novartis
The U.S. Food and Drug Administration accepted Novartis' filing for tislelizumab to treat esophageal cancer. 
Via The Motley Fool
Exposures Product Safety
African Research Foundation Partners With International Pharmaceutical Industry to Strengthen Capacity for Health Innovation in Africa
SOURCE: International Federation of Pharmaceutical Manufacturers & Associations 
Via 3BL Media
Exposures COVID-19
Green Hygienics Holdings To Raise $100M Via Green Bond Offering
Hemp company Green Hygienics Holdings Inc. (OTCQB:GRYN) is ... 
Via Benzinga
A Day Of Huge Market Moves
It was a day of huge market moves and several reporting companies. Trudeau won but did not get a parliamentary majority. 
Via Talk Markets
DGTL Holdings Inc. Signs New $400k Contract with Nasdaq Listed Online Sports Gaming Client
Toronto, Ontario--(Newsfile Corp. - September 21, 2021) - DGTL Holdings Inc. (TSXV: DGTL) ("DGTL" or the "Company") reports that its subsidiary Hashoff... 
Via Newsfile
Topics Artificial Intelligence
Exposures Artificial Intelligence
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
Novartis Adds Vision Loss Gene Therapy Program Via Arctos Acquisition
Novartis AG (NYSE: NVS) has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its... 
Via Benzinga
Pharma, Tech and Finance
Good news on some drugs was not enough to boost stock markets. 
Via Talk Markets
Why Did Deutsche Bank Downgrade This Big Pharma Stock?
Deutsche Bank has downgraded Novartis AG (NYSE: NVS) to Sell from Hold with a price target of CHF 70, down from CHF 80. Analyst Emmanuel... 
Via Benzinga
Novartis' Kisqali Combo Therapy Extends Survival By One Year In Breast Cancer Patients
Novartis AG (NYSE: NVS) announced results of the final overall survival (OS) analysis of Phase 3 MONALEESA-2 study, which evaluated Kisqali (ribociclib) in... 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
38 39 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.